TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TOFO Insulin Combination Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients aged 20-75 years old with type 2 diabetes mellitus (T2DM).~* Hemoglobin A1c ≥7.5% - ≤10.5% and FPG ≤220 mg/dL.~* Basal bolus (BB), Bolus, Premix, Basal supported oral therapy (BOT) regimens used for more than 12 weeks before screening.~* Stable dose (-/+20%) of insulin and no change in the dose of oral hypoglycemic agents for more than 12 weeks before screening.~* Only Dipeptidyl peptidase-4 inhibitor is allowed for basal supported oral therapy (BOT) regimen.~* Body mass index (BMI) ≥18.5 kg/m\^2 and \<35.0 kg/m\^2.~* No change of antihypertensive, anti-hypercholesterolemia and uric acid lowering drug 4 weeks before screening.~Exclusion criteria:~* Type 1 diabetes mellitus.~* Pregnancy or lactation.~* Severely uncontrolled glycemic situation.~* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening.~* History of myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months.~* A measured serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women.~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 times the upper limit of the reference range at the central laboratory test facility.~* Has previously received treatment with the investigational product.~* Has received treatment with another investigational product or non-approved drug within 3 months before tests for provisional enrolment.~* Corticosteroid therapy for 14 or more days in total within 8 weeks before tests for provisional enrolment (excluding those used for localized effects, such as drugs for topical \[skin\] application, eye drops and sprays).~* Patients who are frequently experiencing orthostatic hypotension.~* Required a change in the dosing regimen for the following drugs within 4 weeks before tests for provisional enrolment:~* Lipid-lowering drug~* Antihypertensive drug~* Thyroid hormone preparation~* Uric acid lowering drug~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- tofogliflozin (Type: EXPERIMENTAL): Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
- placebo (Type: PLACEBO_COMPARATOR): Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pathologically confirmed colorectal cancer~2. Signed consent~Exclusion Criteria:~1. Tumor can be resected by endoscopic mucosal resection(EMR)~2. History of malignancy~3. Bowel obstruction or intestinal perforation~4. Evidence of metastasis by physical examination, chest roentgenogram and computed tomography of liver and pelvis~5. Acute diseases and acute attack of chronic diseases~6. Psychiatric history~7. Deformity of spine~8. ASA score≥Ⅳ~9. Mid-low rectal cancer~10. Pregnant woman~11. Needing to use Chinese traditional patent drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Treatment （Laparoscopic） (Type: ACTIVE_COMPARATOR): Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
- FTMD Treatment （Laparoscopic） (Type: ACTIVE_COMPARATOR): Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
- Conventional Treatment（Open Surgery） (Type: ACTIVE_COMPARATOR): Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
- FTMD Treatment（Open Surgery） (Type: ACTIVE_COMPARATOR): Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Willing to provide a written informed consent prior to receiving any study-specific procedures or assessments.~* Diagnosed with a solid malignant tumor and has not previously received chemotherapy.~* Scheduled to receive chemotherapy conducive to regimens outlined in the study protocol.~Exclusion criteria:~* Not received any investigational product within 30 days of enrollment into the study.~* Must not be pregnant.~* Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol.~* Must not be scheduled to receive radiation therapy to the abdomen or to the pelvis within seven (7) days prior to starting study medication.~* Must not be currently under treatment for a condition which may cause nausea or vomiting (i.e., active peptic ulcer disease, gastric obstruction).~* Must not have a history of peptic ulcer disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Over 18 years old~2. Has a diagnosis of rheumatoid arthritis~3. Stable DMARDs for at least 1 month (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine)~4. Disease activity score DAS28/ESR \> 3.2 or all must be met: TJC (tender joint count)\>=4, SJC (swollen joint count)\>=4~5. Must be able to understand information in the Informed Consent and comply with study requirements~6. Total ultrasound synovitis (inflammation of joint-lining membrane) power Doppler score \>=1 for at least 2 joints and total synovitis score \>=1 for at least 1 joint~Exclusion Criteria:~1. Current or prior use of biologic drugs (TNF inhibitors, IL-6 inhibitors, CD20 inhibitors, IL-1 inhibitors, etc.)~2. Pregnancy or breast feeding~3. Daily prednisone \> 10mg (stable dose for at least 1 month)~4. Intra-articular steroid injection of the wrist or joints within last 2 months~5. History of a concomitant autoimmune disease such as lupus, psoriatic arthritis~6. History of cancer~7. Previous exposure to abatacept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous Abatacept (Type: EXPERIMENTAL): All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 6 months to 48 months of age (inclusive)~* Diagnosis of DMD with a deletion mutation amenable to exon 51 skipping~* Parent(s) or legal guardian(s) who is willing to provide written informed consent~Exclusion Criteria:~* Received treatment that might have an effect on muscle strength or function within 12 weeks prior to dosing~* Received previous or current treatment with any experimental treatment~* Clinically significant illness other than DMD~* Clinically significant laboratory abnormality~* Any other condition that could interfere with the participation in the study.

- Gender: MALE
- Minimum Age: 6 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Eteplirsen (Type: EXPERIMENTAL): Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of loud snoring but no observed breathing pauses by bed partner (or only very mild obstructive sleep apnea on a previous sleep study within the prior year) will be enrolled.~* Very mild sleep apnea is defined here as an apnea-hypopnea index (AHI) \< 10/hour).~* This assumes that the AHI is computed using hypopnea defined as a 30% drop in the flow signal associated with a 4% or greater arterial oxygen desaturation.~Exclusion Criteria:~* Prior upper airway surgery~* Daytime sleepiness (Epworth sleepiness scale \>12/24), (obesity BMI \> 35 kg/M2)~* Significant arterial oxygen desaturation defined as 5 minutes or more with an arterial oxygen desaturation less than 88%~* Severe insomnia with less than 4 hours of sleep per night~* Uncontrolled psychiatric disorder~* Any disorder causing facial weakness~* Pregnancy~* Temporal mandibular joint problems.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Facial-Flex (Type: OTHER): The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 6 months to 10 years.~* mono-infection with P. falciparum detected by microscopy;~* parasitaemia of 250 - 200,000/μl asexual forms;~* presence of axillary temperature ≥37.5 °C or history of fever during the past 24 hours~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the parents or guardians of children.~Exclusion Criteria:~* mRDT negative~* presence of general danger signs in children aged 6 months to 10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);~* weight under 5 Kg~* mixed or mono-infection with another Plasmodium species detected by microscopy;~* presence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm in children ≤ 59 months; or BMI of \<16 in children aged 5 years and above)~* presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* regular medication, which may interfere with antimalarial pharmacokinetics;~* history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older~* Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease~* Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC~* Existence of at least 1 measurable lesion by RECIST v1.1~* Adequate hematological, renal and liver function~* Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1~* Life expectancy longer than 6 months~Exclusion Criteria:~* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature~* Any unresolved toxicities from prior systemic therapy~* Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations~* Previous dosing with vascular endothelial growth factor (VEGF) inhibitor~* Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy~* Use of prohibited concomitant medication~* Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection~* Fertile men or women of childbearing potential not using adequate contraception.~Other inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB238 / paclitaxel / carboplatin (Type: EXPERIMENTAL): Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
- Avastin / paclitaxel / carboplatin (Type: ACTIVE_COMPARATOR): Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kisspeptin in the Evaluation of Delayed Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adolescent Boys~* ages 13.5-17 years~* testicular volume \<4 mL OR 4-8 ml with no change in the past 6 months by Prader orchidometer~* first morning (before 9AM) LH \<2 mIU/mL and testosterone \<50 ng/dL~Adolescent Girls~* ages 12-17 years~* Tanner stage I OR II breast development with no change in the past 6 months~* first morning (before 9AM) LH \<2 mIU/mL and estradiol \<20 pg/ml~All Subjects:~* bone age less than chronological age~* weight ≥ 28 kg~* body mass index \>10th percentile and \<+3 SDS for bone age~* blood pressure \>5th percentile and \<95th percentile for bone age and height~* white blood cell counts, platelet counts, electrolytes, thyroid stimulating hormone (TSH), free thyroxine (T4) within reference range for age~* erythrocyte sedimentation rate \<2X the upper limit of the reference range for age~* hemoglobin within reference range for girls of the same chronological age~* blood urea nitrogen (BUN), creatinine, prolactin not elevated~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no more than 2X the upper limit of the reference range~* Insulin-like growth factor 1 (IGF-1) within reference range for bone age~Exclusion Criteria:~All Subjects:~* history or presence of underlying condition that could cause delayed puberty (chronic illness, weight loss, abnormal cranial magnetic resonance imaging (MRI))~* history of an allergic drug reaction

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Kisspeptin, GnRH (Type: EXPERIMENTAL): Intravenous (IV) administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female of non-childbearing potential or male~* Age above or equal to 18 years at the time of signing informed consent~* Body mass index (BMI) greater than or equal to 27.0 kg/m\^2~* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening~* Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening~* Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at maximum tolerated or effective dose as judged by the investigator: metformin with or without Sodium-glucose co-transporter-2 (SGLT2) inhibitor~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed~* Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 60 ml/min/1.73m\^2 by central laboratory at screening~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cagrilintide 2.4 mg and semaglutide 2.4 mg (Type: EXPERIMENTAL): Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
- Cagrilintide 2.4 mg and placebo (semaglutide) (Type: ACTIVE_COMPARATOR): Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
- Semaglutide 2.4 mg and Placebo (cagrilintide) (Type: ACTIVE_COMPARATOR): Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from the subject prior to enrolment;~* Female between, and including, 18 and 25 years of age at the time of enrolment;~* Subjects must be free of obvious health problems;~* Not pregnant and having no plan for pregnancy;~Exclusion Criteria:~* Pregnant or breastfeeding or having plan for pregnancy during the whole study (Month 0-7);~* Previous vaccination against HPV;~* Having severe allergic history or other immunodeficiency;~* Chemotherapy and other immunosuppressive agents using;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- 30μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
- 60μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
- 90μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
- hepatitis B vaccine (Type: PLACEBO_COMPARATOR): Participants in this arm would receive hepatitis B vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete